- Home
- ACI vs AXSM Comparison
ACI vs AXSM Comparison
Compare ACI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACI | AXSM |
|---|---|---|
| Founded | 1860 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.0B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ACI | AXSM |
|---|---|---|
| Price | $17.30 | $185.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 21 |
| Target Price | $22.75 | ★ $190.57 |
| AVG Volume (30 Days) | ★ 10.1M | 876.5K |
| Earning Date | 01-07-2026 | 02-23-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $81,719,800,000.00 | $561,263,000.00 |
| Revenue This Year | $4.70 | $67.43 |
| Revenue Next Year | N/A | $58.11 |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | 2.24 | ★ 65.83 |
| 52 Week Low | $15.80 | $86.99 |
| 52 Week High | $23.20 | $191.50 |
Technical Indicators
Market Signals| Indicator | ACI | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 50.62 | 66.56 |
| Support Level | $16.57 | $172.05 |
| Resistance Level | $17.22 | $191.50 |
| Average True Range (ATR) | 0.54 | 5.78 |
| MACD | 0.03 | 0.64 |
| Stochastic Oscillator | 70.50 | 76.12 |
Price Performance
Historical ComparisonAbout ACI Albertsons Companies Inc.
Albertsons is the second-largest supermarket operator in the United States with about 2,300 stores across a variety of banners. Around 80% of the firm's sales comes from nonperishable and fresh food, of which 26% comes from its portfolio of private brands. The company operates fuel centers at about 20% of its store locations and pharmacies at 75%. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of the outstanding shares.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.